Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
McKesson
AstraZeneca
Daiichi Sankyo
US Army
Express Scripts
UBS
Cipla
Moodys

Generated: October 16, 2017

DrugPatentWatch Database Preview

Wyeth Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for WYETH PHARMS, and when can generic versions of WYETH PHARMS drugs launch?

WYETH PHARMS has thirty-seven approved drugs.

There are twenty-three US patents protecting WYETH PHARMS drugs on WYETH PHARMS drugs in the past three years.

There are three hundred and seventy-two patent family members on WYETH PHARMS drugs in sixty-seven countries and thirty-four supplementary protection certificates in twelve countries.

Summary for Applicant: Wyeth Pharms

International Patents:372
US Patents:23
Tradenames:35
Ingredients:21
NDAs:37
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
PHOSPHOLINE IODIDE
echothiophate iodide
FOR SOLUTION;OPHTHALMIC011963-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Wyeth Pharms Inc
PREMARIN
estrogens, conjugated
TABLET;ORAL004782-003Approved Prior to Jan 1, 1982RXYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
PROTONIX
pantoprazole sodium
TABLET, DELAYED RELEASE;ORAL020987-002Jun 12, 2001ABRXYesNo► Subscribe► SubscribeY► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-004Oct 20, 1997ABRXYesYes► Subscribe► SubscribeY► Subscribe
Wyeth Pharms Inc
PHOSPHOLINE IODIDE
echothiophate iodide
FOR SOLUTION;OPHTHALMIC011963-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
PREMARIN
estrogens, conjugated
TABLET;ORAL004782-004Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
TRECATOR
ethionamide
TABLET;ORAL013026-002Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
PIPRACIL
piperacillin sodium
INJECTABLE;INJECTION050545-006Sep 30, 1985DISCNYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
LODINE XL
etodolac
TABLET, EXTENDED RELEASE;ORAL020584-003Jan 20, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Wyeth Pharms

Paragraph IV activity for WYETH PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
desvenlafaxine succinate
Extended-release Tablets 25 mg
PRISTIQ
5/8/2015
desvenlafaxine succinate
Extended-release Tablets50 mg and 100 mg
PRISTIQ
2/29/2012
piperacillin sodium and tazobactam sodium
For Injection12 g/1.5 g per vial (pharmacy bulk)
ZOSYN
12/6/2011
levonorgestrel and ethinyl estradiol
Tablets0.09 mg/0.02 mg
LYBREL
10/5/2007
venlafaxine hydrochloride
Extended-release Tablets37.5 mg, 75 mg and 150 mg
EFFEXOR XR
5/3/2007
venlafaxine hydrochloride
Tablets25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg
EFFEXOR
11/3/2005
pantoprazole sodium
Delayed-release Tablets20 mg and 40 mg
PROTONIX
2/2/2004

Non-Orange Book Patents for Wyeth Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,326,367 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,291,347Succinate salt of O-desmethyl-venlafaxine► Subscribe
7,449,4552-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,127,404 Tissue selective compounds in the treatment of endometrial proliferation► Subscribe
6,924,281 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,026,508Succinate salt of O-desmethyl-venlafaxine► Subscribe
6,951,852 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indoles as estrogenic agents► Subscribe
7,498,312Compositions containing piperacillin and tazobactam useful for injection► Subscribe
6,232,307 Tissue selective compounds in the treatment of ovarian cancer► Subscribe
7,247,6242-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Wyeth Pharms Drugs

Country Document Number Estimated Expiration
Norway309564► Subscribe
European Patent Office1762249► Subscribe
Uruguay24613► Subscribe
Taiwan555568► Subscribe
Japan4093611► Subscribe
World Intellectual Property Organization (WIPO)9912531► Subscribe
South Korea100824554► Subscribe
Norway20014816► Subscribe
Eurasian Patent Organization007602► Subscribe
Colombia4900051► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Wyeth Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
323Luxembourg► SubscribePRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
2009 00035Denmark► Subscribe
C0001France► SubscribePRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
2016 00016Denmark► SubscribePRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
00C/027Belgium► SubscribePRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
C/GB09/045United Kingdom► SubscribePRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/09/511/001 20090417; UK EU/1/09/511/002 20090417; UK EU/1/09/511/003 20090417; UK EU/1/09/511/004 20090417
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
608Luxembourg► Subscribe91608, EXPIRES: 20220415
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Cipla
Federal Trade Commission
Moodys
Medtronic
Johnson and Johnson
Teva
Argus Health
Dow
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot